

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Oxyneo 15 mg Controlled-Release Tablet (DIN 02372533) manufactured by Purdue Pharma, Apo-Oxycodone CR 15 mg Controlled-Release Tablet (DIN 02394766) manufactured by Apotex Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **May 25, 2022**.

As of **May 25, 2022**, all claims for Apo-Oxycodone CR 15 mg Controlled-Release Tablet (DIN 02394766) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the ADBL to remain as a benefit.

Due to the unavailability of Salinex 0.9% Nasal Solution (NPN 80024901) manufactured by Exzell Pharma, Salinex 9 mg/ml Nasal Spray (NPN 80024381) manufactured by Exzell Pharma will be considered a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*. This grouping was added to the Critical Supply Product List on **May 25, 2022**.

As of **May 25, 2022**, all claims for Salinex 9 mg/ml Nasal Spray (NPN 80024381) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. and Teva Canada Limited that the shortages for pms-Progesterone 100 mg Capsule (DIN 02476576) and Teva-Progesterone 100 mg Capsule (DIN 02439913), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **July 11, 2022**. The following grouping was removed from the Critical Supply Product List on **June 8, 2022**.

PROGESTERONE

100 MG CAPSULE

00002476576	PMS-PROGESTERONE	PMS	\$ 0.3762
00002463113	REDDY-PROGESTERONE	DRL	\$ 0.3762
00002439913	TEVA-PROGESTERONE	TEV	\$ 0.3762
00002166704	PROMETRIUM	ORC	\$ 1.1330

continued next page

continued from previous page

Removal of a temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) manufactured by Pharmascience Inc., Salazopyrin 500 mg Tablet (DIN 02064480) manufactured by Pfizer Canada ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pharmascience Inc. has advised Alberta Blue Cross that the shortage of pms-Sulfasalazine 500 mg Tablet (DIN 00598461) has been resolved.

As a result, Salazopyrin 500 mg Tablet (DIN 02064480) will no longer be considered a temporary benefit for the *ADBL* **after July 11, 2022**. The above grouping was removed from the Critical Supply Product List on **June 9, 2022**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

